论文部分内容阅读
乳腺癌是一种高度异质性的恶性肿瘤,全世界每年约有41万女性死于乳腺癌。1983年全国乳腺癌协会将乳腺癌分为非浸润性癌、早期浸润性癌、浸润性特殊癌和浸润性非特殊癌4大类。近年来,雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER-2)已成为乳腺癌患者免疫组化标志物常规检查项目。三阴性乳腺癌为ER、PR、HER-2均为阴性的乳腺癌。由于无内分泌治疗及针对HER-2的分子
Breast cancer is a highly heterogeneous malignancy, with about 410,000 women dying each year from breast cancer worldwide. In 1983 the National Breast Cancer Association divided breast cancer into non-invasive cancer, early invasive cancer, invasive special cancer and invasive non-specific cancer four categories. In recent years, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) have become routine tests of immunohistochemical markers in breast cancer patients. Triple negative breast cancer ER, PR, HER-2 are negative breast cancer. Due to the absence of endocrine therapy and molecules directed against HER-2